https://www.plenaryai.com/blog daily 0.75 2021-04-09 https://www.plenaryai.com/blog/backpacking-through-europe-rf4p7-yjpbt-z38by-m8eap monthly 0.5 2024-12-16 https://www.plenaryai.com/blog/vegan-trends-amp-fried-chicken-6n2f6-2hjlg-f49ey-7838k monthly 0.5 2024-12-16 https://www.plenaryai.com/blog/music-affects-mood-y5b72-2sd82-s43a8-an7e6 monthly 0.5 2024-12-16 https://www.plenaryai.com/blog/blog-post-title-two-t7f56-k8g2f-w332a-3nemh-js46d monthly 0.5 2024-12-16 https://www.plenaryai.com/blog/blog-post-title-three-wt8cw-mpbhz-67y4g-gk5mw-sa938 monthly 0.5 2024-12-16 https://www.plenaryai.com/blog/blog-post-title-four-c3k55-nmpgy-n97d8-2gf8c-hzn4d monthly 0.5 2024-12-16 https://www.plenaryai.com/technology daily 0.75 2021-06-11 https://www.plenaryai.com/careers daily 0.75 2021-05-13 https://www.plenaryai.com/news daily 0.75 2021-04-09 https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589847896972-M6Z43LS56WX5T1S74A5I/image-asset.jpeg News https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589847898345-D40VLF9LAM9L2XYZ5A1B/image-asset.jpeg News https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1589847897715-EWKVJ35VXQ5P9CDGSYVT/image-asset.jpeg News https://www.plenaryai.com/team daily 0.75 2025-05-09 https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1622565778990-3TWIEJJHED7YZNSO0E4M/Martin%2BPompoer.jpg Team https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1622565970339-NCTQZH01EAI3YUFA7ID4/Stephen%2BRowe.jpg Team https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1623764990219-46OTXEXQZNLZUEREM8VK/DuYong-smallsize.jpg Team https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1623774652190-LNISTTC2SKH87D0GNA7X/LEAL%2Bjeff.jpg Team https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1623940161658-WN8JQTX1CD2Z8QXLZ8CN/image%2B%25289%2529.jpg Team https://www.plenaryai.com/home daily 1.0 2021-12-07 https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1623764858017-0NHZY488760HZIBGCTYR/Plenary_Header_3+%282%29.gif Home PRODUCT PL01 Automated Screening, Diagnostic, and Prognostic Assessment Our Artificial Intelligence (AI) and Deep Learning (DL) solutions help medical imaging professionals interpret the ever-growing number of images they analyze in their research and clinical practices. PlenaryAI has developed a real-time, AI-assisted quantitative assessment tool for molecular images that can objectively and automatically identify, segment, and classify tissue types. Our technology provides real-time, biochemical information to clinicians for detection, diagnosis and assessing response to therapy. In addition to its contribution to the clinical domain, this tool is equally valuable in pre-clinical studies to promote translation of promising new technology to clinical use. https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1622588915670-GON63MZM1QHY7D1PS6GF/Product+2_original+colors.png Home PRODUCT PL02 Machine Learning for Cancer Classification on PET Positron Emission Tomography (PET) images are typically evaluated by radiologists for detection and monitoring of malignant conditions, but this manual process is often time-consuming, expensive, and subject to reader variability. Our machine learning framework automates this image analysis, characterizing malignant lesions on PET images systematically. Our technology has been focused on classifying prostate cancer lesions using an imaging agent that targets the prostate-specific membrane antigen (PSMA). But it can assist in the diagnosis and prognosis of other cancers, as well as PET-based radiation therapy treatment planning. https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1622589156252-5T5GGN1BCRQ39465FROC/product_3.3.png Home PRODUCT PL03 Machine Learning for Parkinson’s Disease Subtype Selection We are unraveling the mysteries of heterogeneous outcomes. Physicians have traditionally relied on observation and communication among themselves to discover new diseases or variants of disorders that affect patient treatments and outcomes. In the case of Parkinson’s disease, we can use machine learning to subtype patients into subgroups who differ with respect to symptoms and signs, which may include deficits related to cognition, motor skills or decreased sense of smell. Such subtyping will enable physicians to educate patients and their families about their prognosis, and enable more appropriate, tailored, treatment. PlenaryAI’s advanced machine learning methods automate and scale this process, combining vast, complex data sets to optimally characterize each patient, indicate divergent outcomes, and discover alternative treatments. https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/c897b641-5c9b-4d8a-a8d1-509f89de0371/gray+background.png Home https://images.squarespace-cdn.com/content/v1/60709ccd65e8d70fd9f8f7f1/1638836088666-LI3JQIN8XVGYTCPDM21R/OV+logo_blk.png Home https://www.plenaryai.com/about daily 0.75 2021-04-09 https://images.squarespace-cdn.com/content/v1/5cee9df5880cbc000150d93b/1561902574874-0TNHDCEXEFFAEJPP4GP2/fran.jpg About https://www.plenaryai.com/privacy-policy-1 daily 0.75 2021-06-17